Private Advisor Group LLC purchased a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Rating) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 4,000 shares of the exchange traded fund's stock, valued at approximately $230,800,000. Private Advisor Group LLC owned 0.23% of ProShares Ultra Nasdaq Biotechnology at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the 2nd quarter worth $290,000. Walleye Capital LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth about $275,000. UBS Group AG lifted its position in ProShares Ultra Nasdaq Biotechnology by 302.0% during the 1st quarter. UBS Group AG now owns 2,034 shares of the exchange traded fund's stock worth $126,000 after acquiring an additional 1,528 shares during the period. Simplex Trading LLC lifted its position in ProShares Ultra Nasdaq Biotechnology by 265.7% during the 3rd quarter. Simplex Trading LLC now owns 1,514 shares of the exchange traded fund's stock worth $72,000 after acquiring an additional 1,100 shares during the period. Finally, Vontobel Holding Ltd. lifted its position in ProShares Ultra Nasdaq Biotechnology by 11.6% during the 1st quarter. Vontobel Holding Ltd. now owns 3,321 shares of the exchange traded fund's stock worth $206,000 after acquiring an additional 344 shares during the period.
Get ProShares Ultra Nasdaq Biotechnology alerts:ProShares Ultra Nasdaq Biotechnology Stock Up 2.7 %
Shares of BIB opened at $54.18 on Friday. The stock has a 50-day moving average of $52.88 and a two-hundred day moving average of $57.08. ProShares Ultra Nasdaq Biotechnology has a one year low of $38.42 and a one year high of $67.31.
ProShares Ultra Nasdaq Biotechnology Company Profile
(Get Rating)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Recommended Stories
- Get a free copy of the StockNews.com research report on ProShares Ultra Nasdaq Biotechnology (BIB)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding BIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Rating).
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.